Dr. F. DuBois Bowman Named 13th President Of Morehouse
Congratulations are in order for public health leader, Dr. F. DuBois Bowman. On Tuesday (May 13), Morehouse named the renowned biostatistician the 13th president of the Atlanta-based HBCU. Dr. Bowman will assume the role on July 15, succeeding President David A. Thomas, who began his tenure in 2018. Dr. Bowman's career story
Dr. Bowman, a distinguished authority in the statistical analysis of complex, large-scale data, became dean of the University of Michigan School of Public Health in 2018. Since taking the helm, Dr. Bowman spearheaded a bold interdisciplinary research initiative focused on addressing critical public health challenges, including firearm injury prevention, urban health equity, infectious disease control, and the advancement of health equity.
According to the University of Michigan School of Public Health website, under Dr. Bowman's guidance, the school's research funding has grown to exceed $100 million annually. He also oversaw the enhancement and expansion of academic programs at the university that currently serves more than 1,200 students.
Dr. Bowman is a member of the National Academy of Medicine and a fellow of both the American Statistical Association and the American Association for the Advancement of Science. For Bowman, a 1992 graduate of Morehouse College, this marks a full-circle moment in his journey as a public health leader. A proud member of Phi Beta Kappa and Omega Psi Phi Fraternity, Inc., he has remained deeply engaged with his alma mater—not only as a two-time Morehouse parent but also as a mentor and advocate.
He has played a key role in creating a pipeline program connecting students from Morehouse and Spelman Colleges to opportunities at the University of Michigan. In recognition of his contributions, Bowman received Morehouse's highest alumni honor in 2019, the Bennie Trailblazer Award, named after the College's sixth president, Dr. Benjamin Elijah Mays. The award recognizes alumni who have made significant contributions to their fields and have served as positive role models for others.
'Returning to Morehouse as its 13th president is the honor of a lifetime,' Dr. Bowman said in a statement. 'This institution shaped who I am—instilling a commitment to excellence, justice, and impact. I am excited to partner with faculty, staff, students, alumni, and supporters to build on our legacy and write the next chapter of Morehouse's transformative story.'
Willie Woods, the chairman of the Morehouse College Board of Trustees, called the former Columbia University and Emory University educator a 'visionary.' Woods expressed his excitement to see how Dr. Bowman will continue to shape and impact Morehouse as president.
'Dr. Bowman's record of visionary leadership, his deep commitment to academic excellence, and his lifelong dedication to Morehouse make him the ideal choice to lead the college into its next era,' Woods shared. 'He brings an extraordinary blend of intellectual rigor, strategic thinking, and values-driven leadership.'
According to 11Alive , President Thomas will step down in June. Prior to the announcement of Dr. Bowman as his successor, the 68-year-old shared with the outlet that he felt the time was right for a transition, a generational shift in leadership that will hopefully breathe new life into Morehouse.
'I think it's time for the baby boomers to leave this stage,' he added. 'The generation behind us has new ideas, new ways of engaging.'
SEE ALSO
Dr. F. DuBois Bowman Named 13th President Of Morehouse was originally published on newsone.com
Black America Web Featured Video
CLOSE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
an hour ago
- Chicago Tribune
Funding cuts ripple across Northwestern, as faculty urge no deal with Trump
Nearly four months have passed since the Donald Trump administration abruptly froze $790 million in federal funding at Northwestern University, and the school's fragile research infrastructure has been pummeled by cuts. Portions of research and clinical trials have ground to a halt. Labs have been instructed to scrutinize every expense, from equipment to personnel. Some teams are even killing off lab mice because it's cheaper than feeding them and cleaning cages. With university President Michael Schill set to appear again before a congressional committee Tuesday, rumors of a possible deal with the White House have gripped campus. But the situation on-the-ground remains dire, according to faculty and staff. 'Let's say they unfreeze the funds. The damage is done,' said Guillermo Oliver, a professor in the Division of Nephrology and Hypertension. 'Let's be clear, this is not going to be, 'OK, back to business.'' Northwestern never received formal notification of the funding freeze in April, which came amid several federal probes into allegations of antisemitism. The Evanston-based university has been spending about $10 million a week to keep research afloat, faculty told the Tribune in June. That's led officials to pursue a string of belt-tightening measures. Last week, the university eliminated more than 400 positions, half of which were already vacant. A month earlier, officials announced changes to employees' health insurance plans and a hiring freeze. While Northwestern pays out-of-pocket for research, departments have urged scientists to crimp spending. The Feinberg School of Medicine, which receives 70% of the university's research funding, has seen the brunt of those cuts — potentially putting lifesaving work at risk, faculty say. The Oliver Lab at Feinberg studies the biological development of the lymphatic system. Each piecemeal reduction has contributed to an environment of uncertainty among its staff. As the freeze drags on, Oliver isn't sure how long he can maintain bare-bones operations. 'We were asked to cut as many costs as we could, in everything,' Oliver said. 'The stressful question is, 'When will this be over?' We have no idea.' Many Northwestern scientists, including Oliver, utilize genetically engineered mice specifically bred for lab work. But animal costs have had to be reduced, too. 'It was not mandatory,' he said. 'Nobody told us, 'You need to reduce your mouse colony by 50%.' Rather it was, 'Try to reduce as much as you can without major impact to your research.'' Infrastructure for labs and clinical trials takes time to develop, and sudden shifts in resources and personnel can jeopardize years of work. That can't be immediately reversed, researchers say. Scott Budinger, chief of pulmonary and critical care in the department of medicine, has spent more than two decades researching drugs to treat pneumonia. While his team is still able to collect vital patient samples, they've been left untouched in a freezer. 'The work on those new drug targets has virtually stopped … All of that work could be gone in several months,' Budinger said. 'If we start to lose the people and lose the expertise, you can't just step in and rebuild that work.' It's unclear how much longer Northwestern can continue to fund research without reimbursement. A university spokesperson did not respond to requests for comment. Northwestern is among the wealthiest universities in the country, with a $14.3 billion endowment. But the school's business model was built on grants: During its 2023-24 fiscal year, it received $1.05 billion in research funding. Amid the pause, the endowment and donors can only offer so much support. Endowments weren't designed to be rainy-day funds or sitting cash. A large portion of the capital is invested in hedge funds and private equity. Much of the pool is also restricted, meaning the funds are reserved by donors for specific purposes — such as scholarships or academic programs. In a typical year, most universities only draw from their year-to-year earnings at a rate of less than 5% of the total endowment. That uncertainty — coupled with perceived threats to academic freedom — has led some scientists to explore opportunities elsewhere, even outside of the U.S. Faculty members have voiced concerns that a potential exodus of researchers could undermine Northwestern's competitiveness on the global stage. It's an option weighed by Benjamin Thomson, an assistant professor of ophthalmology who said he would consider returning to his home country of Canada. 'I've done some looking at positions,' Thomson said. 'I have no immediate intention of leaving, but it's not something I would necessarily be averse to if the situation were different.' In recent weeks, several Ivy League schools have settled with the Trump administration to restore paused funding. Columbia University, for example, will pay more than $220 million to the federal government and implement several initiatives aimed at addressing antisemitism on campus. The Wall Street Journal reported that Northwestern officials were also in talks with White House. A university spokesperson declined to comment, but rumors of a deal have already rippled through campus. Northwestern's Concerned Faculty Group, which represents hundreds of members, said in a statement last week that a settlement would make the school 'complicit in an assault on institutions of higher education.' The Trump administration has leveraged federal funding to force universities to comply with its agenda, the statement said. 'This is extortion,' said Laura Beth Nielsen, a professor of sociology and member of the group. 'We need to resolve the situation, but not at the expense of academic freedom.' Meanwhile, Schill is set to appear again before the House Committee on Education and the Workforce in a transcribed interview closed to the press Tuesday. When he last appeared before the Republican-led body in May 2024, he was grilled for hours about the campus environment for Jewish students. A committee spokesperson did not directly comment on when or if the transcription might be made public. 'We all agree that if there is an antisemitism problem on campus, that the university is under an obligation to take action to stop it,' said Paul Gowder, a professor of law. 'But we also all agree that this is a pretext.' The situation has left some faculty conflicted. Many are alarmed by the prospect of yielding to federal pressure, but also recognize that an indefinite funding freeze poses serious risks. Melissa Simon, vice chair for research in the department of general obstetrics and gynecology, was one of the highest-funded Northwestern professors through the National Institutes of Health. In May, her research hub, the Center for Health Equity Transformation, was shuttered with just minutes' notice. Simon suspects Northwestern closed the lab to comply with the Trump administration's crackdown on diversity, equity and inclusion initiatives. A few weeks later, she was allowed to resume the center's research under a new name, Elevate Lab. But the whiplash has been draining. 'I'm fighting every day. It has been demoralizing and exhausting,' Simon said. 'But how much will so-called negotiation with Trump help?' Last week, Simon was forced to lay off her program assistant, Chisom Chima, her only staffer not funded by grant money. Both women were devastated. 'It's very heartbreaking, not just to lose a job, but to lose a job working with this team,' Chima said. 'Everyone has been on edge.' Next month, undergraduate students will begin to trickle back to campus. It won't be a typical academic year. When Schill announced the layoffs last week, he called the period of the freeze 'among the most difficult in our institution's 174-year history.' But the message among faculty is clear: The university is at a tipping point for research. 'I think if the freeze were reversed today, we could get things back,' Budinger said. 'I don't think it's too late yet, but time is running out.'
Yahoo
2 hours ago
- Yahoo
Regional Health Properties, Inc. and SunLink Health Systems, Inc. Announce Receipt of Shareholder Approvals for Merger
Atlanta, GA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ('Regional') (OTCQB: RHEP) (OTCQB: RHEPA) and SunLink Health Systems, Inc. ('SunLink') (NYSE American: SSY) jointly announced today that, at special meetings of their respective shareholders each held on August 4, 2025, Regional shareholders and SunLink shareholders approved the merger of SunLink with and into Regional, with Regional as the surviving corporation pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of April 14, 2025, as amended, by and between Regional and SunLink. The SunLink shareholders also approved at their special meeting, on a non-binding advisory basis, the SunLink merger-related compensation proposal. The closing of the proposed merger remains subject to customary closing conditions. The Regional shareholders also approved at their special meeting the issuance of shares of Regional common stock, no par value, and Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares, no par value per share (the 'Series D Preferred Stock'), in connection with the merger. Descriptions of the Series D Preferred Stock were previously disclosed in Regional's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 18, 2025, and included in Regional's joint proxy statement/prospectus filed with the SEC on June 25, 2025, as supplemented or amended. About Regional Health Properties, Inc. Regional Health Properties, Inc., headquartered in Atlanta, Georgia, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit About SunLink Health Systems, Inc. SunLink Health Systems, Inc., headquartered in Atlanta, Georgia, is the parent company of subsidiaries that own and operate Carmichael's Cashway Pharmacy. For more information, visit NO OFFER OR SOLICITATION Communications in this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the 'Securities Act'). ADDITIONAL INFORMATION INVESTORS ARE URGED TO READ THE TENDER OFFER STATEMENT ON SCHEDULE TO FILED WITH THE SEC ON JULY 18, 2025 REGARDING A PROPOSED TENDER OFFER, AS WELL AS THE SCHEDULE 14D-9 FILED BY REGIONAL ON AUGUST 1, 2025 AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements can often, but not always, be identified by the use of words like 'believe', 'continue', 'pattern', 'estimate', 'project', 'intend', 'anticipate', 'expect' and similar expressions or future or conditional verbs such as 'will', 'would', 'should', 'could', 'might', 'can', 'may', or similar expressions. These forward-looking statements include, but are not limited to, statements relating to the expected timing and benefits of the proposed merger between Regional and SunLink, including statements of Regional's goals, intentions and expectations; statements regarding Regional's business plan and growth strategies; and statements regarding the tender offer. These forward-looking statements are subject to significant risks, assumptions and uncertainties that may cause results to differ materially from those set forth in forward-looking statements, including, among other things: the risk that the businesses of Regional and SunLink will not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; expected revenue synergies and cost savings from the merger may not be fully realized or realized within the expected time frame; revenues following the merger may be lower than expected; customer, vendor and employee relationships and business operations may be disrupted by the merger; the ability to obtain required regulatory approvals and the ability to complete the merger on the expected timeframe; the costs and effects of litigation and the possible unexpected or adverse outcomes of such litigation; the ability of Regional and SunLink to meet the initial or continued listing requirements or rules of the NYSE American LLC or the OTCQB, as applicable, and to maintain the listing or trading, as applicable, of securities thereon; possible changes in economic and business conditions; the impacts of epidemics, pandemics or other infectious disease outbreaks; the existence or exacerbation of general geopolitical instability and uncertainty; possible changes in monetary and fiscal policies, and laws and regulations; competitive factors in the healthcare industry; Regional's dependence on the operating success of its operators; the amount of, and Regional's ability to service, its indebtedness; covenants in Regional's debt agreements that may restrict its ability to make investments, incur additional indebtedness and refinance indebtedness on favorable terms; the effect of increasing healthcare regulation and enforcement on Regional's operators and the dependence of Regional's operators on reimbursement from governmental and other third-party payors; the relatively illiquid nature of real estate investments; the impact of litigation and rising insurance costs on the business of Regional's operators; the effect of Regional's operators declaring bankruptcy, becoming insolvent or failing to pay rent as due; the ability of any of Regional's operators in bankruptcy to reject unexpired lease obligations and to impede its ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations; Regional's ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; and other risks and factors identified in (i) Regional's cautionary language included under the headings 'Statement Regarding Forward-Looking Statements' and 'Risk Factors' in the Regional Annual Report, and other documents subsequently filed by Regional with the SEC and (ii) SunLink's cautionary language included under the headings 'Forward-Looking Statements' and 'Risk Factors' in SunLink's Annual Report on Form 10-K for the year ended June 30, 2024, and other documents subsequently filed by SunLink with the SEC. These forward-looking statements speak only as of the date they are made and neither Regional nor SunLink undertake any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this press release. In addition, Regional's and SunLink's past results of operations do not necessarily indicate either of their anticipated future results, whether the merger is effectuated or not. Regional ContactBrent Morrison, CFAChief Executive Officer & PresidentRegional Health Properties, (404) SunLink Contact Robert M. Thornton, Executive Officer(770) 933-7004Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
3 hours ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
